Related Experiment Video
Updated: Aug 26, 2026
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Clinical Evaluation of [18F]AlF-NOTA-GL01 PET/CT in patients with solid tumors: a prospective comparison with
Xingyu Mu1, Shengyuan Xu2, Zihao Chen1,3
1Department of Nuclear Medicine, The First Affiliated Hospital, Guilin Medical University, Guilin, 541001, China.
Purpose:
This prospective study evaluated the clinical performance of [18F]AlF-NOTA-GL01 PET/CT, examined the relationship between tracer uptake and tumor FAP expression, and performed head-to-head comparisons with [18F]FDG and [18F]FAPI-42 PET/CT in exploratory subset.
Methods:
Between August 2025 and March 2026, 106 patients completed [18F]AlF-NOTA-GL01 PET/CT and paired-tracer PET/CT; 103 underwent paired [18F]FDG PET/CT and 3 underwent paired [18F]FAPI-42 PET/CT. Lesion SUVmax and tumor-to-background ratio (TBR) were compared on a lesion basis. In tumors with available histology, FAP expression was quantified by immunohistochemistry and correlated with lesion SUVmax. Patient- and lesion-based diagnostic performance was assessed against a composite reference standard.
Results:
The final cohort comprised 106 patients (55 men, 51 women; mean age, 61.3 ± 9.0 years), including 102 malignant tumors and 4 benign lesions. Lesion [18F]AlF-NOTA-GL01 SUVmax correlated strongly with tumor FAP expression (r = 0.754, P < 0.001) and increased across low, intermediate, and high FAP-expression tumors. In patient-based analysis, [18F]AlF-NOTA-GL01 showed higher sensitivity than [18F]FDG (98.9% vs. 90.8%, P = 0.039), with comparable specificity (62.5% vs. 62.5%, P = 1.000). In lesion-based analysis, [18F]AlF-NOTA-GL01 outperformed [18F]FDG in sensitivity (96.4% vs. 71.3%, P < 0.001), specificity (50.6% vs. 24.7%, P = 0.003), and accuracy (90.5% vs. 65.3%, P < 0.001). In an exploratory subset, [18F]AlF-NOTA-GL01 showed lower normal-organ background and higher lesion-to-background ratios than [18F]FAPI-42.
Conclusion:
[18F]AlF-NOTA-GL01 uptake was associated with tumor FAP expression and demonstrated higher lesion-based sensitivity and accuracy than [18F]FDG in this single-center cohort, although specificity remained modest. These findings support further clinical development of [18F]AlF-NOTA-GL01 as a broadly applicable, scalable FAP-targeted PET agent.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...